Drug intelligence / Profile preview

Respivax

Development stage: Unknown
Lead developer: BulBio-NCIPD
Modality: Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

**Respivax** is a polybacterial immunostimulant available in tablet formulations such as 25mg and 50mg doses, primarily used to enhance the body's natural resistance and specific immunity against various respiratory tract infections. It works by stimulating immune responses through exposure to multiple bacterial components, making it suitable for preventive treatment in humans prone to recurrent respiratory issues. Developed as an over-the-counter or non-prescription medicine, it is marketed in regions including Europe and online pharmacies targeting such conditions.[1][2][3]

Brand names: Respivax

Beyond the preview

Go deeper on Respivax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Respivax.

Explore the full profile